Our portfolio company, Arkeon Biotechnologies has secured over €10M EUR in funding after securing €6.5M in seed funding last March and later announcing an additional raise of €4M.
Arkeon use gas fermentation technologies to convert CO2 into functional, carbon-negative ingredients for food.
Arkeon CEO Gregor Tegl says, they “are very pleased to have the support of our new strategic partners as well as the strong commitment of our existing investors to make the sustainable production of proteinogenic ingredients a reality”. The new funds will go towards the expansion of its proprietary technology and the planning of a new R&D center. This funding will play a crucial role in making “the sustainable production of proteinogenic ingredients a reality”.